Tuesday, June 16, 2020 2:57:02 PM
GGB,
Most here believe a partnership will be in our future, I certainly do. I believe it's that partnership that will put a price on our company that establishes a point to grow from. I cannot say what price the company will accept for such a partnership with the partner taking an equity position in the company, but I certainly don't believe that $5 or more is out of the question. Time will tell.
I believe that post approval we'll certainly be in double digits, and if in fact either, or both products prove they work in more than one cancer, triple digits will be in the cards if the company remains independent. I'm speaking about what may happen in the next 5 to 10 years, not something that could happen overnight. It will take additional trials, but the partnership should bring in the funds needed to get them underway, then it will be up to what they prove.
Gary
Most here believe a partnership will be in our future, I certainly do. I believe it's that partnership that will put a price on our company that establishes a point to grow from. I cannot say what price the company will accept for such a partnership with the partner taking an equity position in the company, but I certainly don't believe that $5 or more is out of the question. Time will tell.
I believe that post approval we'll certainly be in double digits, and if in fact either, or both products prove they work in more than one cancer, triple digits will be in the cards if the company remains independent. I'm speaking about what may happen in the next 5 to 10 years, not something that could happen overnight. It will take additional trials, but the partnership should bring in the funds needed to get them underway, then it will be up to what they prove.
Gary
Recent NWBO News
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 04/21/2026 04:15:08 AM
- Form POS AM - Post-Effective amendments for registration statement • Edgar (US Regulatory) • 04/16/2026 09:25:30 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/07/2026 04:30:50 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 03/31/2026 09:04:37 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/15/2026 10:06:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/02/2026 10:14:59 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 11/28/2025 09:43:27 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 11/25/2025 10:23:07 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/20/2025 09:26:03 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 11/19/2025 09:15:48 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/14/2025 09:44:21 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/31/2025 04:29:10 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/30/2025 08:40:05 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/24/2025 04:28:38 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/14/2025 06:22:26 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2025 09:00:38 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 07/01/2025 09:04:38 PM
